Drugs / siG12D LODER
siG12D LODER
also known as
Panc1 (krasgat)
Small interfering RNA (siRNA) targets KRAS via inhibition
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01188785 | Jan 2011 → Dec 2013 | pancreatic ductal adenocarcinoma | Silenseed Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01676259 | Mar 2018 → Oct 2022 | pancreatic ductal adenocarcinoma | Silenseed Ltd | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | siG12D-LODER | “PURPOSE: The miniature biodegradable implant siG12D-LODER™ was inserted into a tumor and released a siRNA drug against KRAS(G12D) along four months.” PMID 26009994 ↗ Sep 2015 |
| Known as | Panc1 (krasgat) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594499 ↗ |
| Action | Inhibit | “stable administration of KRASG12D siRNA has the potential to silence and lead to apoptosis of such cancer cells” NCT01188785 ↗ |
| Modality | Small interfering RNA (siRNA) | “This novel siRNA based drug was studied, in combination with chemotherapy, as targeted therapy for Locally Advanced Pancreatic Cancer (LAPC).” PMID 26009994 ↗ Sep 2015 |
| Route | Other | “The siG12D LODER/s will be placed in the subject's tumor using an EUS biopsy needle.” NCT01188785 ↗ |
| Target | KRAS | “released a siRNA drug against KRAS(G12D)” PMID 26009994 ↗ Sep 2015 |